-transparent.png){kind=logo}
Disodium pamidronate (APD) is a potent inhibitor of bone resorption, with less risk of defective mineralization than earlier bisphosphonates. We assessed the response to six spaced low-dose intravenous infusions of APD given at intervals of approximately 6 weeks followed by weekly infusions if bone turnover remained abnormal. Three groups of 10 patients were studied, each group receiving infusions of 15, 30, or 45 mg. Hydroxyproline excretion fell by 62% and alkaline phosphatase was reduced by 72%, with no difference between the dose levels. A total of 21 patients (70%) achieved normal levels of bone turnover, indicating that low-dose infusions of APD are a safe and effective treatment for Paget's disease.
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
January 1995,
The British journal of clinical practice,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
February 1993,
Acta medica portuguesa,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
January 1991,
Klinische Wochenschrift,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
January 1996,
Revue du rhumatisme (English ed.),
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
January 1989,
Clinical and laboratory haematology,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
October 2003,
Zhonghua yi xue za zhi,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
January 1989,
Schweizerische medizinische Wochenschrift,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
February 1999,
Bone,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
February 1992,
British journal of rheumatology,
M D Stone, and
A B Hawthorne, and
D Kerr, and
G Webster, and
D J Hosking
May 1990,
Bone and mineral,
